Cantor Fitzgerald Reiterates Overweight on Gracell Biotechnologies, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Gracell Biotechnologies (NASDAQ:GRCL) and maintained a $20 price target.
September 05, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Gracell Biotechnologies and maintained a $20 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Gracell Biotechnologies. The maintained price target of $20 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100